Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01828554 · ClinicalTrials.gov registry record · NA
Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight
A NA study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT01828554: Completed NA study, sponsored by University of Wisconsin, Madison.
NCT01828554 is a NA study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01828554, a NA study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this research study is to find what happens to capecitabine in the body when dosed using actual versus ideal body weight in subjects with advanced tumors and elevated body mass index.
Primary Outcome
AUC will be calculated for Capecitabine dosed for Ideal Body Weight during the first cycle (days 1-7) and for Capecitabine dosed for Actual Body Weight for first cycle (days 9-15). \[nonlinear mixed effects modeling approach\]
Interventions
- DRUG Xeloda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-06 |
| Est. Completion | 2018-04 |
| Phase | NA |
What the finished NCT01828554 record still lists
NCT01828554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Xeloda is the first listed.
NCT01828554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01828554 about?
NCT01828554 is a clinical study titled "Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight". The purpose of this research study is to find what happens to capecitabine in the body when dosed using actual versus ideal body weight in subjects with advanced tumors and elevated body mass index.
What is the current status of trial NCT01828554?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2013-06. Estimated completion is 2018-04.
What interventions are being tested in trial NCT01828554?
The interventions under investigation include: Xeloda (DRUG).
Who is sponsoring clinical trial NCT01828554?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01828554's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia